Speaker: Philip Newland-Jones, MPharm MRPharmS MSc IPP MFRPS ADVII
After the webinar, participants should be able to:
- Understand the current recommendations for indications for starting, increasing or decreasing glucose-lowering medicines with individual patient characteristics for people with T2DM
- Differentiate between each class of glucose-lowering medication and its respective role in the management of T2DM
- Discuss the safety information and contraindications of T2DM medications and the role of the pharmacist in deliver patient-centred diabetes care.
This webinar aims To provide new and update existing knowledge of diabetes management and treatment options for type 2 diabetes mellitus (T2DM).
Philip Newland-Jones is a Consultant Pharmacist in Diabetes and Endocrinology and has worked at University Hospitals Southampton National Health Service (NHS) Foundation Trust, UK since 2008. He is a current committee member of the UK Clinical Pharmacy Association Diabetes and Endocrinology Group and Chairs the regional Diabetic subgroup of the District Prescribing Committee. At Southampton he takes a leading role in the trusts patient improvement framework for diabetes with numerous patient safety projects previously undertaken and ongoing.
At a national level he is the lead pharmacist for NHS England Diabetes Clinical Reference Group, and sits on the diabetes parliamentary think tank. He has a key role with pharmaceutical input into the direction of inpatient diabetes care at University Hospital Southampton and works in a specialist practitioner role on a day to day basis reviewing inpatients with diabetes issues. His dedication to education ensures the rest of his time is taken up educating doctors, nurses, allied healthcare professionals and students within secondary care, primary care and university settings.